Identified gaps
The absence of sufficient “in-vivo” laboratory studies to evaluate the antimicrobial efficacy of ABHRs.
Clinical studies including healthcare providers involved in direct patient care are essential to evaluate the impact of skin tolerability, acceptability, application frequency and compliance on HAIs.
The lack of randomized controlled trials to determine the effectiveness of various ABHR formats in reducing HAIs and pathogen transmission.